IP Library Granted Patent US 12,257,457
Granted Patent B2
US 12,257,457 · App. 17/864,212 · Granted Mar 25, 2025

Neuromodulation techniques for perturbation of physiological systems

Inventors: Christopher Michael Puleo (Niskayuna, NY); Victoria Eugenia Cotero (Troy, NY); Jeffrey Michael Ashe (Gloversville, NY); John Frederick Graf (Ballston Lake, NY)
Assignee: GENERAL ELECTRIC COMPANY
A61N7/00A61N1/0536A61N1/36017A61N2007/0026A61N2007/0073A61N2007/0078
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,257,457
App. No.
17/864,212
Granted
Mar 25, 2025
Kind
B2
Abstract

Embodiments of the present disclosure relate to techniques for inducing physiological perturbations in a subject via neuromodulation, e.g., peripheral neuromodulation of a region of interest of an organ. The nature and degree of the perturbations may be related to the subject's clinical condition. Accordingly, an assessment of one or more characteristics of the perturbations may be used to determine a clinical condition of the subject.

Claims (33)

1. A method of causing a change in concentration of one or more molecules in a subject, the method comprising:

directing energy of an energy application device at a region of interest of a subject, wherein the region of interest is in a liver;

applying the energy to the region of interest in the liver to cause the change in concentration of the one or more molecules as a result of applying the energy, wherein the one or more molecules comprises glucose or insulin;

assessing the change in concentration of the one or more molecules relative to a baseline concentration of the one or more molecules, wherein assessing the change in concentration of the one or more molecules comprises determining a concentration of glucose or insulin at a plurality of time points after applying the energy and determining that a trend in the concentration at the plurality of time points is indicative of a return to a baseline glucose concentration within a predetermined time period; and

determining that the subject is in a category selected from a first category or a second category, wherein the first category is responsive to neuromodulation and the second category is non-responsive to neuromodulation and the subject is determined to be in the second category when a change in the concentration relative to the baseline concentration is less than a predetermined threshold change.

2. The method of claim 1 , wherein assessing the change in concentration of the one or more molecules comprises:

determining a concentration of the one or more molecules of interest at a first time point after applying the energy; and

determining a concentration of the one or more molecules of interest at a second time point after applying the energy, the second time point being after the first time point.

3. The method of claim 2 , wherein assessing the change in concentration of the one or more molecules comprises determining a difference between the concentration of the one or more molecules of interest at the first time point and the second time point, determining a slope of the concentration of the one or more molecules of interest between the first time point and the second time point, or both.

4. The method of claim 1 , wherein assessing the change in concentration of the one or more molecules comprises determining a time between a trough and a recovery peak of the one or more molecules of interest.

5. The method of claim 1 , comprising causing the energy application device to deliver treatment energy to the region of interest, wherein the treatment energy is applied according to a treatment protocol selected based on a circulating glucose concentration.

6. The method of claim 1 , wherein the subject is not fasted and wherein applying the energy causes an approximated fasting state.

7. A method of causing a change in concentration of a molecule of interest in a subject, the method comprising:

directing energy of an energy application device at a region of interest of a subject;

applying the energy to the region of interest to cause the change in concentration of the molecule of interest as a result of applying the energy;

assessing the change in concentration of the molecule of interest at one or more time points after the application, wherein assessing the change in concentration of the molecule of interest comprises:

determining a concentration of the molecule of interest at a first time point after applying the energy;

determining a concentration of the molecule of interest at a second time point after applying the energy, the second time point being after the first time point;

determining a difference between the concentration of the molecule of interest at the first time point and the second time point, determining a slope of the concentration of the molecule of interest between the first time point and the second time point, or both; and

determining, that the subject is in a category selected from a first category or a second category, wherein the first category is responsive to neuromodulation and the second category is non-responsive to neuromodulation and the subject is determined to be in the second category when a change in the concentration relative to the baseline concentration is less than a predetermined threshold change.

8. The method of claim 7 , wherein the region of interest is in a pancreas and wherein assessing the change in concentration of the molecule of interest comprises determining a concentration of circulating insulin at a plurality of time points after the applying and comparing the concentration at the plurality of time points to a baseline concentration of insulin to determine a responsiveness of the subject to neuromodulation therapy.

9. The method of claim 7 , wherein the region of interest is in a spleen and wherein assessing the change in concentration of the molecule of interest comprises determining a change in a population of immune cells or concentration of cytokines or immune markers after delivering the energy.

10. The method of claim 7 , wherein the region of interest is in a liver and wherein assessing the change in concentration of the molecule of interest comprises determining a concentration of glucose or insulin at a plurality of time points after the applying and determining that a trend in the concentration at the plurality of time points is indicative of a return to a baseline glucose concentration within a predetermined time period.

11. The method of claim 7 , wherein assessing the change in concentration of the molecule of interest comprises receiving image data to identify a systemic response caused by the applying.

12. A method of causing a change in concentration of one or more molecules in a subject, the method comprising:

directing energy of an energy application device at a region of interest of a subject, wherein the energy application device delivers treatment energy to the region of interest and wherein the treatment energy is applied according to a treatment protocol based on a circulating glucose concentration;

applying the energy to the region of interest to cause the change in concentration of the one or more molecules as a result of applying the energy;

assessing the change in concentration of the one or more molecules relative to a baseline concentration of the one or more molecules at one or more time points after applying the energy; and

determining, based on the assessing, that the subject is in a category selected from a first category or a second category, wherein the first category is responsive to neuromodulation and the second category is non-responsive to neuromodulation and the subject is determined to be in the second category when a change in the concentration relative to the baseline concentration is less than a predetermined threshold change.

13. The method of claim 12 , wherein the region of interest is in a pancreas and wherein assessing the change in concentration of the one or more molecules comprises determining a concentration of circulating insulin at a plurality of time points after the applying and comparing the concentration at the plurality of time points to a baseline concentration of insulin to determine a responsiveness of the subject to neuromodulation therapy.

14. The method of claim 12 , wherein the region of interest is in a spleen and wherein assessing the change in concentration of the one or more determining a change in a population of immune cells or concentration of cytokines or immune markers after delivering the energy.

15. The method of claim 12 , wherein the region of interest is in a liver and wherein assessing the change in concentration of the one or more molecules comprises determining a concentration of glucose or insulin at a plurality of time points after the applying and determining that a trend in the concentration at the plurality of time points is indicative of a return to a baseline glucose concentration within a predetermined time period.

16. The method of claim 12 , wherein assessing the change in concentration of the one or more molecules comprises receiving image data to identify a systemic response caused by the applying.

Assignments (1)
NUNC PRO TUNC ASSIGNMENT Recorded May 8, 2025
From: GENERAL ELECTRIC COMPANY
To: GE PRECISION HEALTHCARE LLC
Reel/Frame 071225/0218 →
Continuity (2)
Division 16399692 · Apr 30, 2019
Related Publication 20220362587A1 · Nov 17, 2022
References Cited (22)
US 6615081B1 · Boveja · 2003 [cited by applicant]
US 8591419B2 · Tyler · 2013 [cited by applicant]
US 20060073097A1 · Ma et al. · 2006 [cited by applicant]
US 20120271133A1 · Gal et al. · 2012 [cited by applicant]
US 20130184728A1 · Mishelevich · 2013 [cited by applicant]
US 20160236012A1 · Zderic et al. · 2016 [cited by applicant]
US 20170100605A1 · Schwab et al. · 2017 [cited by applicant]
US 20170333708A1 · Conde et al. · 2017 [cited by applicant]
US 20180028841A1 · Konofagou et al. · 2018 [cited by applicant]
US 20190117977A1 · Puleo et al. · 2019 [cited by applicant]
US 20200054228A1 · Puleo · 2020 [cited by examiner]
JP 2015513437A · 2015 [cited by applicant]
WO 2015069446A1 · 2015 [cited by applicant]
WO 201602875A1 · 2016 [cited by applicant]
WO 2018081763A1 · 2018 [cited by applicant]
WO 20180181826A1 · 2018 [cited by applicant]
Castellanos et al., “Ultrasound Stimulation of Insulin Release from Pancreatic Beta Cells as a Potential Novel Treatment for Type 2 Diabetes,” Ultrasound Medical Biology, vol. 43 Issue: 6 pp. 1210-1222, Jun. 2017. [cited by applicant]
International Application No. PCT/US2017/059394—International Search Report and Written Opinion mailed Feb. 13, 2018. [cited by applicant]
International Application No. PCT/IB2020/054901—International Search Report and Written Opinion mailed Aug. 18, 2020. [cited by applicant]
International Application No. PCT/US2020/038665—International Search Report and Written Opinion mailed Nov. 5, 2020. [cited by applicant]
JP application 2021-564086 filed Dec. 15, 2021—Office Action issued Apr. 3, 2024; Machine Translation; 8 pages. [cited by applicant]
JP2015513437, Machine Translation of English Abstract, Espacenet search Jul. 2, 2024; 1 page. [cited by applicant]